

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | — | — | 1 | — | — | — | — | 1 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
| Drug common name | CANTUZUMAB RAVTANSINE |
| INN | cantuzumab ravtansine |
| Description | Cantuzumab Ravtansine (humanized mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies; maytansinoid derivatives |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | — |
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1742998 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | RNQ8JQ4R9P (ChemIDplus, GSRS) |
